PAX6 Is Expressed in Pancreatic Cancer and Actively Participates in Cancer Progression through Activation of the MET Tyrosine Kinase Receptor Gene*
AUTOR(ES)
Mascarenhas, Joseph B.
FONTE
American Society for Biochemistry and Molecular Biology
RESUMO
Tumors of the exocrine pancreas have a poor prognosis. Several proteins are overexpressed in this cancer type, including the MET tyrosine kinase receptor and the transcription factor PAX6. In this report, we find that PAX6(5a), an alternately spliced variant form of PAX6, is expressed in pancreatic carcinoma cell lines at higher levels than the canonical PAX6 protein. Both protein forms of PAX6 bind directly to an enhancer element in the MET promoter and activate the expression of the MET gene. In addition, inhibition of PAX6 transcripts leads to a decline in cell growth and survival, differentiation, and a concurrent reduction of MET protein expression. These data support a model for a neoplastic pathway, where expression of a transcription factor from development activates the MET receptor, a protein that has been directly linked to protumorigenic processes of resisting apoptosis, tumor growth, invasion, and metastasis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2785681Documentos Relacionados
- Activation of the human PAX6 gene through the exon 1 enhancer by transcription factors SEF and Sp1
- Proapoptotic Function of the MET Tyrosine Kinase Receptor through Caspase Cleavage
- Activating mutations for the Met tyrosine kinase receptor in human cancer
- Mutually regulated expression of Pax6 and Six3 and its implications for the Pax6 haploinsufficient lens phenotype
- The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase